Equities research analysts expect that Novavax (NASDAQ:NVAX) will report ($0.14) earnings per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Novavax’s earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.15). Novavax reported earnings of ($0.16) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 12.5%. The firm is expected to announce its next earnings report on Monday, May 14th.
On average, analysts expect that Novavax will report full year earnings of ($0.57) per share for the current fiscal year, with EPS estimates ranging from ($0.83) to ($0.42). For the next year, analysts anticipate that the firm will post earnings of ($0.57) per share, with EPS estimates ranging from ($0.71) to ($0.34). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Novavax.
Novavax (NASDAQ:NVAX) last announced its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). The firm had revenue of $10.40 million during the quarter, compared to analysts’ expectations of $7.98 million. During the same quarter last year, the business earned ($0.21) EPS. Novavax’s quarterly revenue was up 92.6% on a year-over-year basis.
A number of research analysts have recently issued reports on NVAX shares. BidaskClub upgraded Novavax from a “hold” rating to a “buy” rating in a research report on Thursday, March 15th. B. Riley set a $10.00 target price on Novavax and gave the company a “buy” rating in a research report on Thursday, March 1st. Citigroup lowered Novavax from a “buy” rating to a “neutral” rating and set a $1.00 target price on the stock. in a research report on Tuesday, December 19th. Chardan Capital reiterated a “hold” rating on shares of Novavax in a research report on Thursday, March 1st. Finally, S&P Equity Research decreased their target price on Novavax from $1.81 to $1.35 in a research report on Wednesday, January 10th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. Novavax has a consensus rating of “Hold” and a consensus target price of $3.43.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its stake in Novavax by 30.8% in the 3rd quarter. Wells Fargo & Company MN now owns 446,831 shares of the biopharmaceutical company’s stock valued at $509,000 after purchasing an additional 105,117 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in Novavax by 6.2% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 1,225,018 shares of the biopharmaceutical company’s stock valued at $1,397,000 after purchasing an additional 71,047 shares during the last quarter. Virtus Fund Advisers LLC acquired a new position in Novavax in the 4th quarter valued at $329,000. Virtu Financial LLC raised its stake in Novavax by 11,061.4% in the 4th quarter. Virtu Financial LLC now owns 1,124,842 shares of the biopharmaceutical company’s stock valued at $1,395,000 after purchasing an additional 1,114,764 shares during the last quarter. Finally, Brown Advisory Inc. raised its stake in Novavax by 54.8% in the 4th quarter. Brown Advisory Inc. now owns 251,900 shares of the biopharmaceutical company’s stock valued at $312,000 after purchasing an additional 89,200 shares during the last quarter. 36.88% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:NVAX remained flat at $$1.82 during midday trading on Friday. The stock had a trading volume of 4,754,370 shares, compared to its average volume of 8,507,528. Novavax has a 52-week low of $0.73 and a 52-week high of $2.75. The stock has a market cap of $627.62, a price-to-earnings ratio of -2.88 and a beta of 2.38. The company has a quick ratio of 2.76, a current ratio of 2.76 and a debt-to-equity ratio of -3.12.
COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Anticipate Novavax (NVAX) Will Post Earnings of -$0.14 Per Share” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/14/zacks-analysts-anticipate-novavax-nvax-will-post-earnings-of-0-14-per-share.html.
Novavax, Inc, together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen.
Get a free copy of the Zacks research report on Novavax (NVAX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.